This article is more than 5 years old. Information may no longer be current.

VIDEO: Anti–PD-1 immunotherapy confers ‘encouraging’ survival benefit in metastatic melanoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — Joseph Markowitz, MD, PhD, a medical oncologist in the department of cutaneous oncology at Moffitt Cancer Center, offers insights into a study presented at AACR Annual Meeting that showed more than one-third of patients with advanced melanoma treated with the anti–PD-1 antibody nivolumab (Opdivo, Bristol Myers Squibb) survived 5 years.

That is double the survival rate for patients with metastatic melanoma diagnosed between 2005 and 2011, according to SEER data.

“This study is very encouraging, but we also need future studies to figure out how to treat those 70% of patients who are not surviving to the 5-year mark,” Markowitz told HemOnc Today.